Phase I study of hypofractionated dose-escalated @entity1514 radiotherapy for XXXX .

@entity1 @entity137 @entity5 @entity2910 @entity900 @entity1514 @entity2879 @entity204
PURPOSE: To determine the maximal tolerated dose of hypofractionated @entity1514 radiotherapy with concurrent chemotherapy for @entity5 @entity1 . METHODS AND MATERIALS: Three radiotherapy regimens were used. Radiotherapy was given in two phases: @entity1 initially received 20 Gy in 10 fractions to gross @entity5 plus uninvolved mediastinal nodes, followed by a boost to gross disease of 30, 38, or 42 Gy in 15 fractions. Radiotherapy was planned with conformal techniques. All @entity1 received four cycles of @entity900 (25 mg/m2) and @entity2879 (100 mg/m2) chemotherapy. Radiotherapy commenced with Day 1 of Cycle 2 of chemotherapy. All complete/near-complete responders were offered prophylactic cranial irradiation. The maximal tolerated dose of radiotherapy was based on the dose that caused unacceptably high rates of radiotherapy-related @entity137 . RESULTS: Thirteen @entity1 were accrued. All @entity1 who commenced radiotherapy received all prescribed chemo- and radiotherapy. There were no treatment-related @entity204 . There was one Grade 3 acute nonhematologic @entity137 in the 50-Gy group. Of the 6 @entity1 given 58 Gy, 3 experienced acute Grade 3 @entity2910 . With a median follow-up of 7 months, median overall survival was 9.5 months. CONCLUSIONS: The maximal tolerated dose of @entity1514 radiotherapy with concurrent chemotherapy on this trial was 50 Gy in 25 daily fractions.
